3.6. The Combination of GILT and a NFKB Family Inhibitor (NFKB-I) Significantly Reduced the Viable Primary Blasts from FLT3mut AML Patients Ex Vivo. The gene discussed is NFKB1; the disease is acute myeloid leukemia.